Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice.
Oppong-Damoah, A., Curry, K. E., Blough, B. E., Rice, K. C., & Murnane, K. S. | Psychopharmacology | 15 July 2019
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants
Sessa, B., Sakal, C., O’Brien, S., & Nutt, D. | BMJ Case Reports CP | 15 July 2019
Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
Rodrigues, A. V., Almeida, F. J., & Vieira-Coelho, M. A. | Journal of psychoactive drugs | 25 April 2019
Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport
Coleman, J. A., Yang, D., Zhao, Z., Wen, P. C., Yoshioka, C., Tajkhorshid, E., & Gouaux, E. | Nature | 24 April 2019
A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy.
Sessa, B., Higbed, L., & Nutt, D. | Frontiers in Psychiatry | 20 March 2019
Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.
Marton, S., González, B., Rodríguez, S., Miquel, E., Martínez-Palma, L., Pazos, M., ... & Scorza, C. | Frontiers in pharmacology | 5 March 2019
The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis
Argento, E., Tupper, K. W., & Socias, M. E. | International Journal of Drug Policy | 7 February 2019
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. | PloS one | 6 February 2019
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review.
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., ... & Pogarell, O. | European archives of psychiatry and clinical neuroscience | 31 January 2019
Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats
Sakloth, F., Leggett, E., Moerke, M. J., Townsend, E. A., Banks, M. L., & Negus, S. S. | Experimental and clinical psychopharmacology | 10 January 2019
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case series of Patients With Depression and Alcohol Use Disorder
Yoon, G., Petrakis, I. L., & Krystal, J. H. | JAMA psychiatry | 9 January 2019
Metabolite Profiling of Antiaddictive Alkaloids from Four Mexican Tabernaemontana Species and the Entheogenic African Shrub Tabernanthe iboga (Apocynaceae)
Krengel, F., Chevalier, Q., Dickinson, J., Santoyo, J. H., & Reyes-Chilpa, R. | Chemistry & biodiversity | 7 January 2019
Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence
Knuijver, T., Belgers, M., Markus, W., Verkes, R. J., van Oosteren, T., & Schellekens, A. | Journal of clinical psychopharmacology | 1 December 2018
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder
Barsuglia, J. P., Polanco, M., Palmer, R., Malcolm, B. J., Kelmendi, B., & Calvey, T. | Progress in brain research | 25 October 2018
Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
Corkery, J. M. | Progress in brain research | 12 October 2018
DARK Classics in Chemical Neuroscience: Ibogaine.
Wasko, M. J., Witt-Enderby, P. A., & Surratt, C. K. | ACS chemical neuroscience | 9 October 2018
LSD Administered as a Single Dose Reduces Alcohol Consumption in C57BL/6J Mice.
Alper, K., Dong, B., Shah, R., Sershen, H., & Vinod, K. Y. | Frontiers in pharmacology | 31 August 2018
Therapeutic Potential Ascribed to Ayahuasca by Users in the Czech Republic
Horák, M., Hasíková, L., & Verter, N. | Journal of psychoactive drugs | 30 August 2018
A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification
Davis, A. K., Renn, E., Windham-Herman, A. M., Polanco, M., & Barsuglia, J. P. | Journal of psychoactive drugs | 18 July 2018
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. | Journal of Psychopharmacology | 25 June 2018
Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes
Mash, D. C., Duque, L., Page, B., & Allen-Ferdinand, K. | Frontiers in Pharmacology | 5 June 2018
Psychedelic therapy as a complementary treatment approach for alcohol use disorders
Eischens, P., & Atherton, W. L. | Journal of Psychedelic Studies | 30 May 2018
Ayahuasca and Its DMT- and β-carbolines – Containing Ingredients Block the Expression of Ethanol-Induced Conditioned Place Preference in Mice: Role of the Treatment Environment
Cata-Preta, E. G., Serra, Y. A., Moreira-Junior, E. D. C., Reis, H. S., Kisaki, N. D., Libarino-Santos, M., ... & Costa, J. L. | Frontiers in pharmacology | 29 May 2018
The epidemiology of 5-methoxy- N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. | Journal of Psychopharmacology | 30 April 2018